CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2

卷:12

Article

关键词: CYSTIC-FIBROSIS;    CHLORIDE CHANNEL;    TARGETS;   

DOI  :  10.3390/cells12050776

来源: SCIE

【 摘 要 】

Several reports have indicated that SARS-CoV-2 infection displays unexpected mild clinical manifestations in people with cystic fibrosis (pwCF), suggesting that CFTR expression and function may be involved in the SARS-CoV-2 life cycle. To evaluate the possible association of CFTR activity with SARS-CoV-2 replication, we tested the antiviral activity of two well-known CFTR inhibitors (IOWH-032 and PPQ-102) in wild type (WT)-CFTR bronchial cells. SARS-CoV-2 replication was inhibited by IOWH-032 treatment, with an IC50 of 4.52 mu M, and by PPQ-102, with an IC50 of 15.92 mu M. We confirmed this antiviral effect on primary cells (MucilAir (TM) wt-CFTR) using 10 mu M IOWH-032. According to our results, CFTR inhibition can effectively tackle SARS-CoV-2 infection, suggesting that CFTR expression and function might play an important role in SARS-CoV-2 replication, revealing new perspectives on the mechanisms governing SARS-CoV-2 infection in both normal and CF individuals, as well as leading to potential novel treatments.